Organoid Culture Harvest Timing Patents: Leaders & White Space 2026
Organoid Culture Harvest Timing Patents: Who Holds the Harvest Window
One assignee leads the ranked field with 11 records against a long tail where the fifth-ranked holder has only 2 and the tenth has 1. Filings sat at zero in 2017, rose to a peak of 10 in 2020, and after a quiet 2021 (1 filing) climbed to 4 by 2024 — a 300% increase over that three-year span. 2025 and 2026 figures will fill in further as publication catches up.
- 1LIFE TECHNOLOGIES CORP11
- 2CELLARTGEN INC8
- 3THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV6
- 4THE KITASATO INSTITUTE3
- 5TSINGHUA UNIVERSITY2
See the full organoid culture harvest timing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on organoid culture harvest timing?
One assignee leads the ranked field with 11 of the 34 records in scope, well ahead of the rest of the ranking. The fifth-ranked holder has only 2 records and the tenth has 1, showing a sharp drop-off after the leader. This pattern suggests the field has one organisation with broad early coverage and a long tail of smaller filers rather than several evenly matched competitors.
Is filing activity in organoid harvest timing increasing or slowing down?
Filings peaked at 10 in 2020, dropped to 1 in 2021, and then grew back to 4 by 2024 — a 300% increase over that three-year span. 2025 and later figures will rise further as publication catches up, since publication typically lags actual filing by around 18 months. Based on the complete years available, the trend through 2024 points to renewed growth rather than a decline.
What technology areas do these patents mostly cover?
Most records (91.2% of the 34 in scope) carry IPC class C12N, covering microorganism and genetic-engineering culture methods. Bioreactor and apparatus claims (C12M) appear in 32.4% of records, and material-testing claims (G01N) in 29.4%, with smaller shares in enzyme/DNA measurement, peptides, medicinal preparations and biocide-related classes. Because a single record can carry multiple IPC classes, these shares add up to more than 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Organoid Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.